Literature DB >> 8750289

Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection.

E Gratacós1, P J Torres, J Vidal, J Font, E Antolin, V Cararach, A Fortuny.   

Abstract

Anticardiolipin antibodies were measured in 60 pregnant women with acute parvovirus B19 infection. Test results for eight (13.3 per cent) women were positive for anticardiolipin antibody. Six of these eight women became negative later, yielding a prevalence of anticardiolipin antibodies of 3.3 per cent (2/60) 6 months after acute parvovirus B19 infection. Anticardiolipin antibody positivity was not associated with an increased risk of abortion, fetal death, or maternal complications. This study suggests that there is an elevated frequency of anticardiolipin antibodies in pregnant women with acute parvovirus B19, probably representing an epiphenomenon. However, this is not associated with an adverse maternal or perinatal outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750289     DOI: 10.1002/pd.1970151205

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  3 in total

1.  Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection.

Authors:  Yoshihide Asano; Maiko Sarukawa; Takeo Idezuki; Syoichiro Harada; Kenzo Kaji; Ichiro Nakasu; Atsuyuki Igarashi
Journal:  Clin Rheumatol       Date:  2006-01-19       Impact factor: 2.980

2.  Antiphospholipid antibodies in HIV-positive patients.

Authors:  Liliana Galrão; Carlos Brites; Maria Luíza Atta; Ajax Atta; Isabella Lima; Fernanda Gonzalez; Fernanda Magalhães; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

Review 3.  Systemic lupus erythematosus and parvovirus B-19: casual coincidence or causative culprit?

Authors:  Marianne C Severin; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.